Arbutus Biopharma Q1 revenue surges on Moderna settlement

Arbutus Biopharma

13/05/2026 12:42

Overview

US infectious disease drugmaker's Q1 revenue surged on license revenue from Moderna litigation settlement

Company posted net income of $169.7 mln, reversing a loss in the prior-year quarter

Outlook

Arbutus expects to receive $178.7 mln from the Moderna settlement in July 2026

Company says FDA Fast Track designation for imdusiran may expedite development and review

Result Drivers

LITIGATION SETTLEMENT - Q1 revenue surge driven by license revenue from Genevant related to Moderna settlement

COST REDUCTIONS - Lower research and development expenses due to workforce reduction and discontinuation of in-house research

LEGAL FEES - Higher general and administrative expenses driven by legal fees related to Moderna settlement, partly offset by cost-cutting

Company press release: ID:nGNX26HPpf

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$179.10 mln
$750,000 (2 Analysts)
Q1 EPS
$0.87


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Arbutus Biopharma Corp is $5.00, about 16% above its May 12 closing price of $4.31

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)